6-丙基烟腈 | 118419-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-丙基烟腈
• 英文名称: 5-Cyano-2-propylpyridine
• 英文别名: 6-Propylpyridine-3-carbonitrile
• CAS: 118419-89-9
• 化学式: C₉H₁₀N₂
• mdl: MFCD06739104
• 分子量: 146.192
• InChiKey: TYOXNPNZXKKQJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-丙基烟腈 在 硫酸 作用下， 生成 6-丙基烟酸
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  2-oxo-6-propyl-1,2-dihydropyridine-3-carbonitrile 在 palladium on activated charcoal 五氯化磷 、 氢气 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 6-丙基烟腈
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012

文献信息

• [EN] IMIDAZO '1,2-A' PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES<br/>[FR] COMPOSES DE 1,2-A' PYRAZINE IMIDAZO INTERAGISSANT AVEC LES PROTEINES KINASES
  申请人：BIOFOCUS DISCOVERY LTD

  公开号：WO2005085252A1

  公开（公告）日：2005-09-15

  The present invention relates to a novel compounds of formula I, to pharmaceutical compounds, to processes for their preparation, as well as to the use of the compounds in the inhibition of protein kinases, in particular serine/threonine kinases, more particularly mitogen activated protein kinase, more particularly the c-Jun NH2-teminal kinases (JNKs). The invention also relates to the compounds for use in medicine and particularly n the prevention and/or treatment of a wide variety of diseases including inflammatory disorders, cancer, angiogenesis, diabetes, metabolic disease and neurological disorders.

  本发明涉及一种式I的新型化合物，以及制备这些化合物的药物化合物的方法，以及化合物在抑制蛋白激酶中的应用，特别是丝氨酸/苏氨酸激酶，更具体地是丝氨酸/苏氨酸激酶，更具体地是c-Jun NH2-teminal激酶（JNKs）。该发明还涉及这些化合物在医学上的应用，特别是在预防和/或治疗包括炎症性疾病、癌症、血管生成、糖尿病、代谢性疾病和神经系统疾病在内的各种疾病中的应用。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：CHATTERJEE Arnab Kumar

  公开号：US20150344471A1

  公开（公告）日：2015-12-03

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

  本发明提供式I的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供包含这种化合物的制药组合物以及使用这种化合物治疗、预防、抑制、改善或消除由疟原虫等引起的疾病的病理学和/或症状学的方法。
• NOVEL BIPYRIDYL DERIVATIVES
  申请人：Sankio Chemical Co., Ltd.

  公开号：EP1231207A1

  公开（公告）日：2002-08-14

  Provided are novel specific dipyridyl derivatives as a useful substance or an intermediate in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence.

  本文提供了新型特异性二吡啶衍生物，可作为有用物质或中间体用于制药、农用化学品、配体、卤化银感光材料、液晶、表面活性剂、电致发光和有机电致发光领域。
• BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP3324977B1

  公开（公告）日：2022-07-13
• US6603007B1
  申请人：——

  公开号：US6603007B1

  公开（公告）日：2003-08-05